• Novanta annual report for year ended Dec. 31, 2025 outlined strategy centered on medical and advanced manufacturing platforms tied to robotics, automation, minimally invasive surgery.
• Bookings increased 14% for full year, supported by faster new product ramp and higher design-win activity.
• Portfolio mix continued to tilt toward medical, with medical end markets at 53% of sales; medical consumables reached 15% of revenue.
• Keonn acquisition closed April 8, 2025, adding RFID solutions with AI-enabled software to Medical Solutions segment.
• Priorities for 2026 set around organic growth execution, deployment of capital for acquisitions, completion of regionalized manufacturing strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novanta Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.